Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nicotinamide
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Ced Service | Gesellschaft für Therapieforschung mbH | German Federal Ministry of Education and Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : CICR-NAM
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2024
Lead Product(s) : Nicotinamide
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Ced Service | Gesellschaft für Therapieforschung mbH | German Federal Ministry of Education and Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Triangel Scientific | Center of New Medical Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 08, 2023
Lead Product(s) : Nicotinamide
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Triangel Scientific | Center of New Medical Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Standard Process Heart and Gut Health Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
April 03, 2023
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
February 17, 2023
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2023
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : Nicotinamide
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Completes Acquisition of Brands from Anglo-French
Details : The acquisition will strengthen Lupin’s business by adding a portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical ...
Product Name : Beplex Forte
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 04, 2022
Lead Product(s) : Nicotinamide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Nicotinamide
Therapeutic Area : Neurology
Study Phase : Phase II/ Phase III
Sponsor : PT SOHO Global Health Tbk
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Nicotinamide
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Sponsor : PT SOHO Global Health Tbk
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : National Institutes of Health | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2019
Lead Product(s) : Nicotinamide
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : National Institutes of Health | National Heart, Lung, and Blood Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicotinamide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nicotinamide in Hemodialysis Patients With Hyperphosphatemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2010
Lead Product(s) : Nicotinamide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable